Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have entered a collaboration focused on developing new medicines for pancreatic ductal adenocarcinoma (PDAC). The collaboration combines MD Anderson’s understanding of potential drivers of PDAC with Boehringer’s drug discovery and development experience and will focus on identifying and developing therapeutic concepts in novel target areas, as well as identify biomarkers to accurately identify patients who wou...